Expert Forum on Bladder Cancer: Future Innovations
“I have no doubt that within 10 years…what we've been basing our treatment strategies and surveillance strategies of high-grade…papillary disease is still going to be there. But, in reality, we're really going to have a much better idea of individual risk stratification and characteristics of their tumors,” says Sam S. Chang, MD, MBA.
EP: 1.Expert Forum on Bladder Cancer: The BCG shortage
EP: 2.Expert Forum on Bladder Cancer: Bladder-sparing treatment
EP: 3.Expert Forum on Bladder Cancer: Nadofaragene Firadenovec for BCG-unresponsive NMIBC
EP: 4.Expert Forum on Bladder Cancer: Recent FDA approvals
EP: 5.Expert Forum on Bladder Cancer: Recent Innovations
EP: 6.Expert Forum on Bladder Cancer: Future Innovations
In this video Sam S. Chang, MD, MBA, Chad R. Ritch, MD, MBA, FACS,and Christopher B. Anderson, MD, MPH,predict what innovations in the bladder cancer space will look like in the coming years. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
